Wnt Signaling Regulation in Bone of Postmenopausal Women With Type 2 1 Diabetes

58 Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral 59 density. We reported that bone formation genes (SOST and RUNX2) and advanced glycation end-60 products (AGEs) were impaired in T2D. Thus, we investigated Wnt signaling regulation and its 61 association with AGEs accumulation in T2D. We obtained bone tissue from 15 T2D and 21 non-62 diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a 63 trend of low mineralized volume in T2D. We showed that gene expression of Wnt agonists LEF-64 1 and WNT10B were lower in T2D. Accordingly, WNT5A and SOST gene expression were 65 higher, while collagen (COL1A1) was lower in T2D. Importantly, AGEs content was associated 66 with SOST and WNT5A, but inversely correlated with LEF-1 and COL1A1. Finally, SOST was 67 also associated with glycemic control and disease duration. These findings suggest that Wnt 68 signaling and AGEs could be the main determinants of bone fragility in T2D.


Introduction
Type 2 diabetes (T2D) is a metabolic disease, with an increasing worldwide prevalence, characterized by chronic hyperglycemia and adverse effects on multiple organ systems, including bones [1].Patients with T2D have an increased fracture risk, particularly at the hip, compared to individuals without diabetes.A recent meta-analysis reported that individuals with T2D have 1.27 relative risk (RR) of hip fracture compared to non-diabetic controls [2].Fragility fractures in patients with T2D occur at normal or even higher bone mineral density compared to healthy subjects, implying compromised bone quality in diabetes.T2D is associated with a reduced bone turnover [3], as shown by lower serum levels of biochemical markers of bone formation, such as .procollagen type1 amino-terminal propeptide (P1NP) and osteocalcin, and bone resorption, Cterminal cross-linked telopeptide (CTX) in diabetic patients compared to nondiabetic individuals [4][5][6][7].Accordingly, dynamic bone histomorphometry of T2D postmenopausal women showed a lower bone formation rate, mineralizing surface, osteoid surface, and osteoblast surface [8].Our group recently demonstrated that T2D is also associated with increased SOST and decreased RUNX2 genes expression, compared to non-diabetic subjects [9].Moreover, we have proved in a diabetic model that a sclerostin-resistant Lrp5 mutation, associated with high bone mass, fully protected bone mass and strength even after prolonged hyperglycemia [10].Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway, a key pathway that regulates bone homeostasis [11].Therefore, we hypothesize that impairment of Wnt pathway through increased sclerostin activity is responsible for low bone turnover and contributes to bone fragility in diabetes.
Diabetes and chronic hyperglycemia are also characterized by increased advanced glycation endproducts (AGEs) production and deposition [12].AGEs may interfere with osteoblast differentiation, attachment to the bone matrix, function, and survival [13,14].AGEs also alter bone collagen structure and reduce the intrinsic toughness of bone, thereby affecting bone material properties [9,15,16].In this work, we propose to dissect Wnt signaling in bone of individuals with T2D and to investigate its relationship with AGEs accumulation.Results confirmed that T2D downregulates Wnt beta/catenin signaling and reduces collagen mRNA levels, in association with AGEs accumulation.

Study subjects
. We enrolled a total of 36 postmenopausal women (15 with T2D and 21 non-diabetic controls)undergoing hip arthroplasty for osteoarthritis, consecutively screened to participate in this study between 2020 and 2022.Diabetes status was confirmed by the treating diabetes physician.Participants were diagnosed with diabetes when they had fasting plasma glucose (FPG) ≥126 mg/dl or 2-h plasma glucose (2-h PG) ≥200 mg/dl during a 75-g oral glucose tolerance test (OGTT); or hemoglobin A1c (HbA1c) ≥6.5% in accordance with the American Diabetes Association diagnostic criteria.Eligible participants were <65 years of age.Exclusion criteria were any diseases affecting bone or malignancy.Additionally, individuals treated with medications affecting bone metabolism such as estrogen, raloxifene, tamoxifen, bisphosphonates, teriparatide, denosumab, thiazolidinediones, glucocorticoids, anabolic steroids, and phenytoin, and those with hypercalcemia or hypocalcemia, hepatic or renal disorder, hypercortisolism, current alcohol or tobacco use were excluded.The study was approved by the Ethics Committee of the Campus Bio-Medico University of Rome and all participants provided written informed consent.

Specimen preparation
Femoral head specimens were obtained during hip arthroplasty.As described previously [9], trabecular bone specimens were collected fresh and washed multiple times in sterile PBS until the supernatant was clear of blood.Bone samples were stored at -80 °C until analysis.

Bone histomorphometry
Trabecular bone from femur heads were fixed in 10% neutral buffered formalin for 24 h and stored in 70% ethanol.Tissues were embedded in methylmethacrylate and sectioned by the Washington University Musculoskeletal Histology and Morphometry Core.Unstained and .TRAP-stained (Sigma) slides were imaged at ×20 high resolution using a NanoZoomer 2.0 with bright field and FITC/TRITC (Hamamatsu Photonics).Images were then analyzed via Bioquant Osteo software according to the manufacturer's instructions and published standards (v18.2.6, Bioquant Image Analysis Corp., Nashville, TN).

RNA extraction and gene expression by RT-PCR
Total RNA from trabecular bone samples was extracted using TRIzol (Invitrogen) following the manufacturer's instructions.The concentration and purity of the extracted RNA were assessed spectrophotometrically (TECAN, InfiniteM200PRO), and only samples with 260/280 absorbance ratio between 1.8 and 2 were used for reverse transcription using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's recommendations.Transcription products were amplified using TaqMan real-time PCR (Applied Biosystems, Carlsbad, CA) and a standard protocol (95°C for 10 minutes; 40 cycles of 95°C for 15 seconds and 60°C for 1 minute; followed by 95°C for 15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds).β-Actin expression was used as an internal control (housekeeping gene).

Statistical analysis
Data were analyzed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA).Patients' characteristics were described using means and standard deviations or medians and interquartile ranges, as appropriate, and percentages.Group data are presented in boxplots with median and interquartile range; whiskers represent maximum and minimum values.Mann-Whitney test was .used to compare variables between groups.Data were analyzed using nonparametric Spearman correlation analysis and the correlation coefficients (r) were used to assess the relationship between variables.
There were no differences in serum calcium, creatinine and serum blood urea nitrogen (Table 1).

Gene Expression
SOST mRNA was significantly higher in T2D than in non-diabetic subjects (Fig. 1A, p<0.0001), whereas there was no difference in DKK1 gene expression between the two groups (Fig. 1B).Of .note, SOST mRNA transcript was very low in the majority of non-diabetic subjects (Fig. 1A).

Discussion
We show that key components of the Wnt/beta-catenin signaling are abnormally expressed in the bone of postmenopausal women with T2D.LEF-1, a transcription factor that mediates responses to Wnt signal and Wnt target gene itself, and WNT10B, an endogenous regulator of Wnt/βcatenin signaling and skeletal progenitor cell fate, are both downregulated in bone of postmenopausal women with T2D.Consistently, expression of the Wnt inhibitor, SOST is increased, suggesting suppression of Wnt/β-catenin signaling in the bone of T2D individuals.
. Interestingly, our data suggest that sclerostin expression is very low in healthy postmenopausal women not affected by osteoporosis.Our data also show that the expression of WNT5A, a noncanonical ligand linked to inhibition of Wnt/beta-catenin signaling was increased, whereas COL1A1 was decreased.The latter finding is consistent with reduced bone formation and suppression of Wnt signaling in T2D.We have previously reported upregulation of SOST and downregulation of RUNX2 mRNA in another cohort of postmenopausal women with T2D [9].Of note, the cohort of T2D subjects studied here had glycated hemoglobin within therapeutic targets, implying that the changes in gene transcription we identified persist in T2D bone despite good glycemic control.
High circulating sclerostin has been reported in diabetes [17,18], and increased sclerostin is associated with fragility fractures [19].Aside from confirming higher SOST expression, we also show that other Wnt/β-catenin osteogenic ligands are abnormally regulated in the bone of T2D postmenopausal women.WNT10B is a positive regulator of bone mass; transgenic overexpression in mice results in increased bone mass and strength [20], whereas genetic ablation of Wnt10b is characterized by reduced bone mass [21,22], and decreased number and function of osteoblasts [21].More to the point, Wnt10b expression is reduced in the bone of diabetic mice [23].Therefore, the reduced WNT10B in human bone we found in the present study further supports the hypothesis of reduced bone formation in T2D.Accordingly, LEF-1 gene expression was also downregulated confirming that Wnt/beta-catenin pathway is decreased in T2D.Importantly, the overexpression of LEF-1 induces the expression of osteoblast differentiation genes (osteocalcin and COL1A1) in differentiating osteoblasts [24].In fact, in this study we also demonstrated that a downregulation of LEF-1 in T2D bone goes along with a downregulation of COL1A1, strengthen data of a reduced production of bone matrix most likely .as the result of reduced osteoblasts synthetic activity in diabetes [8,25].Reduced RUNX2 in T2D postmenopausal women also confirms previous findings (PMID: 32777114) [9] and further supports the notion of reduced osteoblast differentiation or function in diabetes.On the other hand, the contribution of upregulated WNT5A in diabetic bone is more complex.WNT5A regulates Wnt/beta-catenin signaling depending on the receptor availability [26].Non-canonical WNT5A activates β-catenin-independent signaling, including the Wnt/Ca ++ [27] and planar cell polarity pathways [28].Heterozygous Wnt5a null mice have low bone mass with impaired osteoblast and osteoclast differentiation [29].Wnt5a inhibits Wnt3a protein by downregulating beta/catenin-induced reporter gene expression [26].In line with these findings, we showed that there was an increased gene expression of WNT5A in bone of T2D postmenopausal women confirming a downregulated Wnt/beta-catenin signaling and impaired osteoblasts function.
We have previously shown that AGEs content is higher in T2D bone compared to non-diabetic bone, even in patients with well-controlled T2D [9].Here we show that AGEs accumulation is positively correlated with SOST and WNT5A gene expression, and negatively correlated with LEF-1, WNT10B, and COL1A1 mRNA.These findings are consistent with the hypothesis that AGEs accumulation is associated with impaired Wnt signaling and low bone turnover in T2D.
We did not find any abnormalities in histomorphometric parameters in our subjects with T2D, consistent with our previous report [9].Reduced osteoid thickness and osteoblast number were reported in premenopausal T2D women with poor glycemic control compared to non-diabetic subjects but not in the group with good glycemic control [30].Therefore, good glycemic control appears to prevent or rescue any changes in static histologic parameters of bone turnover that might be caused by uncontrolled diabetes.
. Our study has some limitations.One is the cross-sectional design; another one is the relatively small number of T2D subjects enrolled.Moreover, we measured the mRNA abundance of the genes of interest, and we cannot assume that the differences we found reflect differences in protein abundance.Although osteoarthritis may affect some of the genes we studied [31], all study subjects were affected by variable degree of osteoarthritis, and the effect of such potential confounder is not likely to be different between T2D and control subjects.Finally, we did not use the tetracycline double-labeled technique to investigate dynamic bone parameters.
The main strength of our study is that this study is the first to explore the association of AGEs on Wnt pathway in postmenopausal T2D women.Moreover, we measured the expression of several Wnt genes directly on bone samples of postmenopausal T2D women.
In conclusion, our data show that, despite good glycemic control, T2D decreases expression of         .

Figure 1 .
Figure 1.Gene expression analysis in trabecular bone samples.(A) SOST mRNA levels resulted

Figure 2 .
Figure 2. Relationship between AGEs (µg quinine/g collagen) bone content and mRNA level of

Table 1 .
Clinical features of the study subjects

Table 1 .
Results were analyzed using unpaired T-test with Welch's correction.Results are presented as median and interquartile ranges (IQR). .

Table 2 .
Histomorphometric parameters of trabecular bone of the study subjects

Table 2 .
Results were analyzed using unpaired T-test with Welch's correction and are presented as median and interquartile ranges (IQR).